Roche secures rights to Alector's Parkinson's therapy for up to $1.27 billions, Alector shares surge
路透社2026/10/05 12:16Reuters, October 5 – U.S. biotechnology company Alector announced on Monday that Swiss pharmaceutical giant Roche will pay up to 1.27 billion dollars to obtain licensing rights for its experimental Parkinson's disease therapy. Boosted by this news, Alector’s shares surged 72% in pre-market trading. Genentech, a subsidiary of Roche, will pay Alector a 100 million dollar upfront payment, with an additional payment of up to 1.17 billion dollars if the therapy meets certain developmental, regulatory, and sales milestones. Alector will also receive royalty payments. Specific details are as follows: the agreement grants Genentech exclusive global rights to develop, produce, and commercialize AL050, an experimental therapy targeting enzyme deficiency associated with Parkinson’s disease. Genentech will be responsible for the development, regulatory filings, production, and commercialization of the therapy. AL050 is an enzyme replacement therapy designed to address GCase enzyme deficiency—which leads to the buildup of certain fats and increases the risk of Parkinson’s. This deal is the latest in a series of licensing agreements Roche has reached to expand its drug development pipeline. In June, Roche and Nurix Therapeutics entered into a licensing and collaboration agreement involving a blood cancer medication, with a deal value of up to 2.3 billion dollars.
Reuters, October 5 - US biotechnology company Alector announced on Monday that Swiss pharmaceutical company Roche ROPC.S will pay up to $1.27 billion to acquire the rights to its experimental Parkinson's disease therapy ALEC.O, boosting the company's share price by 72% in pre-market trading.
Roche's subsidiary Genentech will pay Alector an upfront payment of $100 million, and if the therapy meets research, regulatory, and sales targets, an additional payment of up to $1.17 billion will be made. Alector will also receive royalty payments.
Details are as follows:
The agreement grants Genentech exclusive global rights to develop, manufacture, and sell AL050, an experimental therapy aimed at addressing enzyme deficiency associated with Parkinson's disease.
Genentech will be responsible for the development, regulatory filings, manufacturing, and commercialization of the therapy.
AL050 is an enzyme replacement therapy designed to address GCase enzyme deficiency — this deficiency can lead to the accumulation of certain fats and increase the risk of Parkinson's disease.
This transaction is the latest in a series of licensing agreements Roche has reached to expand its drug development pipeline.
In June this year, Roche and Nurix Therapeutics NRIX.O entered into a licensing and collaboration agreement (link) involving a blood cancer drug, with a transaction value of up to $2.3 billion.
(For the convenience of non-native English speakers, Reuters has automated the translation of its reports into several other languages. Because automated translations may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of the automated translation text, and provides it solely for the convenience of readers. Reuters assumes no responsibility for any damages or losses resulting from the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley Analyst Says SpaceX Stock Price Could Double
Getlink reports 550,000,000 shares outstanding, 642,851,718 total voting rights as of Sept. 30, 2026
Getlink disclosed 550,000,000 ordinary shares outstanding as of Sept. 30, 2026. Theoretical voting rights totaled 642,851,718. Exercisable voting rights stood at 635,332,063. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Getlink SE published the original content used to generate this news brief via Business Wire (Ref. ID: 202610051200BIZWIRE_USPR_____20261005_BW048564) on October 05, 2026, and is solely responsible for the information contained therein.
European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading
11:12 AM EDT, 10/05/2026 (MT Newswires) -- European equities traded in the US as American depositary receipts opened the week lower late Monday morning, declining 0.14% to 1,883.96 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by lender Banco Santander (SAN) and brewing company Anheuser-Busch InBev (BUD), which advanced 3.2% and 0.8% respectively. They were followed by 3D printer company Materialise (MTLS) and internet browser company Opera (OPRA), which were up 0.6% and 0.3% respectively. The decliners from continental Europe were led by biopharmaceutical company Nokia (NOK) and biopharmaceutical company Cellectis (CLLS), which lost 3.2% each. They were followed by biopharmaceutical company DBV Technologies (DBVT) and petroleum refiner Equinor (EQNR), which decreased 0.9% and 0.4%, respectively. The gainers from the UK were led by biopharmaceutical company Bicycle Therapeutics (BCYC) and software firm Endava plc (DAVA), which climbed 17% and 1.6% respectively. They were followed by medical device maker Smith & Nephew (SNN) and biotech firm Trinity Biotech (TRIB), which increased 1.2% and 1.4% respectively. The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which dropped 3.9% and 1.4% respectively. They were followed by hospitality company InterContinental Hotels Group (IHG) and pharmaceutical company GSK (GSK), which fell 1.1% and 1% respectively.
Bitcoin Returns Reliant on Major Days -- Market Talk
1105 ET - Bitcoin's strong year-over-year returns are more linked to single days of strong moves, according to Zach Pandl of Grayscale in a note. Pandl says removing bitcoin's five best trading days reduces its three-year return from 225% to 95%, with the return falling to 27% without its 10 best days. If you remove the top fifteen days, it turns a three-year gain into an 11% loss. By comparison, removing the Nasdaq's fifteen best days reduces its cumulative return from 109% to 21%. "Given BTC's return and volatility profile, investors looking for long-term capital appreciation can avoid trying to time the market and instead seek consistent, long-term exposure to the asset," Pandl says. Bitcoin is down 0.2% to $85,610, while ethereum falls 0.2% to $2,701. (kirk.maltais@wsj.com) (END) Dow Jones Newswires October 05, 2026 11:05 ET (15:05 GMT)
Crypto prices
More
